Systolic Blood Pressure Reduction and Risk of Cardiovascular Disease andMortality
暂无分享,去创建一个
Tanika N. Kelly | Jing Chen | Jiang He | P. Whelton | Changwei Li | Jiang He | T. Kelly | K. Mills | D. Bundy | Hua He | Katherine T. Mills | Paul K. Whelton | Changwei Li | Hua He | P. Stuchlik | X. Bu | Jing Chen | Patrick Stuchlik | D. Bundy | Xiaoqing Bu | Patrick Stuchlik
[1] S. Anderson,et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis , 2016, The Lancet.
[2] Bo Carlberg,et al. Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses , 2016 .
[3] Daniel W. Jones,et al. SPRINT: What Remains Unanswered and Where Do We Go From Here? , 2016, Hypertension.
[4] M. Woodward,et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis , 2016, The Lancet.
[5] Jackson T. Wright,et al. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. , 2016, The New England journal of medicine.
[6] Bernadette A. Thomas,et al. Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 , 2015, The Lancet.
[7] Dan Jackson,et al. A design-by-treatment interaction model for network meta-analysis with random inconsistency effects , 2014, Statistics in medicine.
[8] J. Cutler,et al. Outcomes of Combined Cardiovascular Risk Factor Management Strategies in Type 2 Diabetes: The ACCORD Randomized Trial , 2014, Diabetes Care.
[9] Jackson T. Wright,et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). , 2014, JAMA.
[10] G. Mancia,et al. Aggressive blood pressure lowering is dangerous: the J-curve: pro side of the arguement. , 2014, Hypertension.
[11] A. Schutte,et al. Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. , 2014, Journal of hypertension.
[12] Sofia Dias,et al. Extending methods for investigating the relationship between treatment effect and baseline risk from pairwise meta‐analysis to network meta‐analysis , 2013, Statistics in medicine.
[13] Lawrence A Leiter,et al. Intensive and Standard Blood Pressure Targets in Patients With Type 2 Diabetes Mellitus: Systematic Review and Meta-analysis. , 2012, Archives of internal medicine.
[14] J. Sterne,et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials , 2011, BMJ : British Medical Journal.
[15] Kevin A Peterson,et al. Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus , 2011 .
[16] S Dias,et al. Checking consistency in mixed treatment comparison meta‐analysis , 2010, Statistics in medicine.
[17] G. Panjrath,et al. The J-curve between blood pressure and coronary artery disease or essential hypertension: exactly how essential? , 2009, Journal of the American College of Cardiology.
[18] K. Reynolds,et al. Global burden of hypertension: analysis of worldwide data , 2005, The Lancet.
[19] G. Lu,et al. Combination of direct and indirect evidence in mixed treatment comparisons , 2004, Statistics in medicine.
[20] Daniel W. Jones,et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. , 2003, Hypertension.
[21] F. Turnbull. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials , 2003, The Lancet.
[22] R. Collins,et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies , 2002, The Lancet.
[23] S. Anderson,et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis , 2016, The Lancet.
[24] Bo Carlberg,et al. Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses , 2016 .
[25] Daniel W. Jones,et al. SPRINT: What Remains Unanswered and Where Do We Go From Here? , 2016, Hypertension.
[26] M. Woodward,et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis , 2016, The Lancet.
[27] A. Rodgers,et al. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. , 2016, The New England journal of medicine.
[28] Dan Jackson,et al. A design-by-treatment interaction model for network meta-analysis with random inconsistency effects , 2014, Statistics in medicine.
[29] J. Cutler,et al. Outcomes of Combined Cardiovascular Risk Factor Management Strategies in Type 2 Diabetes: The ACCORD Randomized Trial , 2014, Diabetes Care.
[30] Jackson T. Wright,et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). , 2014, JAMA.
[31] G. Mancia,et al. Aggressive blood pressure lowering is dangerous: the J-curve: pro side of the arguement. , 2014, Hypertension.
[32] A. Schutte,et al. Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. , 2014, Journal of hypertension.
[33] Jiguang Wang,et al. Effects of Intensive Antihypertensive Treatment on Chinese Hypertensive Patients Older Than 70 Years , 2013, Journal of clinical hypertension.
[34] Julian P T Higgins,et al. Evaluation of inconsistency in networks of interventions. , 2013, International journal of epidemiology.
[35] Sofia Dias,et al. Extending methods for investigating the relationship between treatment effect and baseline risk from pairwise meta‐analysis to network meta‐analysis , 2013, Statistics in medicine.
[36] Alex J. Sutton,et al. Evidence Synthesis for Decision Making 2: A Generalized Linear Modeling Framework for Pairwise and Network Meta-analysis of Randomized Controlled Trials. , 2013 .
[37] S. Solomon,et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial , 2012, The Lancet.
[38] Lawrence A Leiter,et al. Intensive and Standard Blood Pressure Targets in Patients With Type 2 Diabetes Mellitus: Systematic Review and Meta-analysis. , 2012, Archives of internal medicine.
[39] J. Sterne,et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials , 2011, BMJ : British Medical Journal.
[40] C. Bias. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials , 2011 .
[41] W. Elliott. Target Blood Pressure for Treatment of Isolated Systolic Hypertension in the Elderly: Valsartan in Elderly Isolated Systolic Hypertension Study , 2011 .
[42] Kevin A Peterson,et al. Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus , 2011 .
[43] S Dias,et al. Checking consistency in mixed treatment comparison meta‐analysis , 2010, Statistics in medicine.
[44] W. Elliott. The J-Curve Between Blood Pressure and Coronary Artery Disease or Essential Hypertension: Exactly How Essential? , 2010 .
[45] Li-sheng Liu,et al. Blood pressure reduction for the secondary prevention of stroke: a Chinese trial and a systematic review of the literature , 2009, Hypertension Research.
[46] 石井當男. Principal Results of the Japanese Trial to Assess Optimal Systolic Blood Pressure in Elderly Hypertensive Patients (JATOS) , 2008, Hypertension Research.
[47] W. Zidek,et al. Effect of amlodipine on cardiovascular events in hypertensive haemodialysis patients , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[48] Li-sheng Liu,et al. Treatment of hypertension in patients 80 years of age or older. , 2008, The New England journal of medicine.
[49] Anushka Patel,et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial , 2007, The Lancet.
[50] Keith C. Norris,et al. Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[51] G. Lu,et al. Assessing Evidence Inconsistency in Mixed Treatment Comparisons , 2006 .
[52] W. Elliott. Global Burden of Hypertension: Analysis of Worldwide Data , 2006 .
[53] J. Staessen,et al. Blood Pressure Reduction and Cardiovascular Prevention: An Update Including the 2003–2004 Secondary Prevention Trials , 2005, Hypertension Research.
[54] K. Reynolds,et al. Global burden of hypertension: analysis of worldwide data , 2005, The Lancet.
[55] P. Libby,et al. Effect of Antihypertensive Agents on Cardiovascular Events in Patients With Coronary Disease and Normal Blood Pressure The CAMELOT Study: A Randomized Controlled Trial , 2004 .
[56] Hans L. Hillege,et al. Effects of Fosinopril and Pravastatin on Cardiovascular Events in Subjects With Microalbuminuria , 2004, Circulation.
[57] G. Lu,et al. Combination of direct and indirect evidence in mixed treatment comparisons , 2004, Statistics in medicine.
[58] P. Poole‐Wilson,et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial , 2004, The Lancet.
[59] Daniel W. Jones,et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. , 2003, Hypertension.
[60] F. Turnbull. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials , 2003, The Lancet.
[61] K. Fox,et al. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study) , 2003, The Lancet.
[62] M. Pfeffer,et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme , 2003, The Lancet.
[63] W. Desmet,et al. Long term effects of nisoldipine on the progression of coronary atherosclerosis and the occurrence of clinical events: the NICOLE study , 2003, Heart.
[64] S. Lewington. Prospective studies collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies (vol 360, pg 1903, 2002) , 2003 .
[65] Tom Greene,et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. , 2002, JAMA.
[66] Bradley P. Carlin,et al. Bayesian measures of model complexity and fit , 2002 .
[67] P. Mehler,et al. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. , 2002, Kidney international.
[68] Sc Prospective,et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies , 2002 .
[69] Michael E. Miller,et al. Effect of Amlodipine on the Progression of Atherosclerosis and the Occurrence of Clinical Events , 2000, Circulation.
[70] R. Schrier,et al. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. , 2000, Diabetes care.
[71] Andrew Gelman,et al. General methods for monitoring convergence of iterative simulations , 1998 .
[72] R. Holman,et al. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. , 1998 .
[73] Jan A Staessen,et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension , 1997, The Lancet.
[74] W. Shen,et al. Beneficial effects of captopril on prognosis in patients with acute myocardial infarction. Shanghai Secondary Prevention of Acute Myocardial Infarction Study Group. , 1996, Chinese medical journal.
[75] G. Beck,et al. The Effects of Dietary Protein Restriction and Blood-Pressure Control on the Progression of Chronic Renal Disease , 1994 .
[76] L. Passman,et al. The treatment of mild hypertension study. , 1993, JAMA.
[77] M. Mondal,et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. , 1993, The Journal of the Association of Physicians of India.
[78] E. J. Brown,et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. , 1992, The New England journal of medicine.
[79] C. Bulpitt,et al. Mortality and Morbidity Results from the European Working Party on High Blood Pressure in the Elderly Trial , 1985, The Lancet.
[80] A. Helgeland. Treatment of mild hypertension: a five year controlled drug trial. The Oslo study. , 1980, The American journal of medicine.
[81] J. Abernethy. The Australian National Blood Pressure Study: a test of the effectiveness of antihypertensive therapy on the incidence of ischaemic heart disease. , 1976, Australian and New Zealand journal of medicine.
[82] Lull Gf,et al. THE AMERICAN MEDICAL ASSOCIATION. , 1947, Science.